The purpose of the study is to examine whether the regions ensure that hospital physicians’ dual practice is compatible with their work at the hospitals and in accordance with the requirements of the agreement on duty of notification and other rules and regulations in the area. The purpose is also to assess whether the Danish Medicines Agency ensures that the hospital physicians’ association with the pharmaceutical industry does not violate the rules governing the area. The report answers the following questions:
- Are the regions following current rules and guidelines concerning hospital physicians’ dual practice and thereby contributing to ensuring that neither the treatment of patients nor hospital resources are adversely affected by dual practice?
- Is the Danish Medicines Agency checking that hospital physicians’ relationships with the pharmaceutical industry comply with applicable rules?
Rigsrevisionen initiated the study in December 2015.
Read the 1st chapter of the report (PDF)